- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01509469
The Effect of Different Macronutrients on Ileal Brake Activation
Study Overview
Status
Conditions
Detailed Description
The appearance of a food matrix into the duodenum, both during a meal and during the postprandial phase results in a feed-back from different parts of the intestine to the stomach, to the small intestine and to the central nervous system. All these processes inhibit, in concert, food processing in the gastrointestinal tract, satiation and appetite sensations and, consequently, food intake. These processes are involved in the so-called intestinal brake. The location at which the feedback process is initiated determines the severity of the brake effect; the entry of nutrients into the duodenum and jejunum activates the so-called duodenal and jejunal "brakes": negative feedback mechanisms that influence the function of more proximal parts of the gastrointestinal tract. Activation of both of these feedback mechanisms results in reduction of food intake and inhibition of hunger, probably partly by inhibition of gastric emptying rate (thus contributing to enhanced and prolonged gastric distension) and small intestinal transit time. More distal in the small intestine, the ileal brake is a feedback mechanism that results in inhibition of proximal gastrointestinal motility and secretion and increase feelings of satiation and reduction of ad libitum food intake.These results all point to a potentially powerful role of the ileal brake in the regulation of digestion, with direct or indirect impact upon eating behaviour and satiation.
The current scientific data strongly suggest that activation of the ileal brake provides the most powerful feedback mechanism to gastrointestinal transit and, especially, satiety signals and food intake. Most studies have used fat as macronutrient. The effects of several amounts, types and preparations of fat on the ileal brake have previously been investigated and reported.
Until present, the effects of the other macronutrients to induce the ileal brake remain largely unknown. There is evidence that carbohydrates induce the ileal brake. Proteins may also exert effects, although data are scarce and not convincing. However, it becomes more and more accepted that proteins may induce stronger effects on satiation and food intake than fat or carbohydrates.
In this study we're going to investigate the effect of intraileal infusion of casein and sucrose on ileal brake activation.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Limburg
-
Maastricht, Limburg, Netherlands
- Maastricht University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Based on medical history and previous examination, no gastrointestinal complaints can be defined.
- Age between 18 and 55 years. This study will include healthy adult subjects (Male and Female), Women must be taking oral contraceptives. Subjects over 55 years have an increased risk for comorbidities, therefore, subjects over 55 years will not be included.
- BMI between 18 and 29 kg/m2
- Less then 2 'yes' responses in the SCOFF questionnaire (see appendix F1)
- Weight stable over at least the last 6 months
Exclusion Criteria:
- History of severe cardiovascular, respiratory, urogenital, gastrointestinal/ hepatic, hematological/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological/psychiatric diseases, allergy, major surgery and/or laboratory assessments which might limit participation in or completion of the study protocol. The severity of the disease (major interference with the execution of the experiment or potential influence on the study outcomes) will be decided by the principal investigator.
- Use of medication, including vitamin supplementation, except oral contraceptives, within 14 days prior to testing
- Administration of investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principle investigator), in the 180 days prior to the study
- Major abdominal surgery interfering with gastrointestinal function (uncomplicated appendectomy, cholecystectomy and hysterectomy allowed, and other surgery upon judgement of the principle investigator)
- Dieting (medically prescribed, vegetarian, diabetic, macrobiological, biological dynamic)
- Pregnancy, lactation
- Excessive alcohol consumption (>20 alcoholic consumptions per week)
- Smoking
- Blood donation within 3 months before the study period
- Self-admitted HIV-positive state
- Eating disorders detected using the 'SCOFF questionnaire' (in Dutch translation)
- Lactose or cow milk intolerance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Low dose casein
Ileal infusion of low dose casein
|
Ileal infusion of low dose casein (5 gram)
Ileal infusion of high dose casein (15 gram)
|
|
Experimental: High dose casein
Ileal infusion of high dose casein
|
Ileal infusion of low dose casein (5 gram)
Ileal infusion of high dose casein (15 gram)
|
|
Experimental: Low dose sucrose
Ileal infusion of low dose sucrose
|
Ileal infusion of low dose sucrose (4.3 gram)
Ileal infusion of high dose sucrose (12.9 gram)
|
|
Experimental: High dose sucrose
Ileal infusion of high dose sucrose
|
Ileal infusion of low dose sucrose (4.3 gram)
Ileal infusion of high dose sucrose (12.9 gram)
|
|
Placebo Comparator: Placebo
Ileal infusion saline
|
Ileal infusion with saline (180mL in total)
|
|
Active Comparator: Safflower oil
Ileal infusion safflower oil
|
Ileal infusion with safflower oil (6gr safflower oil in water)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Difference in satiation (as measured by VAS) and food intake as measured during an ad libitum meal
Time Frame: 1 day
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Measurements in plasma and/or platelet poor plasma Plasma levels of the gut hormone Cholecystokinin (CCK)
Time Frame: 1 day
|
1 day
|
|
Gastric emptying by using the C13 stable isotope breath test
Time Frame: 1 day
|
1 day
|
|
Small bowel transit time by using lactulose hydrogen breath test
Time Frame: 1 day
|
1 day
|
|
Gallbladder volumes by gallbladder ultrasound
Time Frame: 1 day
|
1 day
|
|
Measurements in plasma and/or platelet poor plasma Plasma levels of the gut hormone Glucagon Like Peptide-1 (GLP-1)
Time Frame: 1 day
|
1 day
|
|
Measurements in plasma and/or platelet poor plasma Plasma levels of the gut hormone peptide YY (PYY)
Time Frame: 1 day
|
1 day
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: A. Masclee, Prof., Maastricht University Medical Centre +
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL36916.068.11
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical ConditionsUnited States
-
Central Hospital, Nancy, FranceNot yet recruiting
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation TechniquesUnited States
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsCompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
Clinical Trials on Casein
-
Serdar BayrakdaroğluCompleted
-
Maastricht University Medical CenterCompletedObesity | Overweight | Satiety | Overeating | Ileal BrakeNetherlands
-
Mead Johnson NutritionNot yet recruiting
-
Texas A&M UniversityCompletedChronic Obstructive Pulmonary DiseaseUnited States
-
ChinaNormNu Skin EnterprisesCompletedMild to Moderate Sleep Disorder | PressureChina
-
Texas A&M UniversityCompleted
-
NIZO Food ResearchFrieslandCampinaCompleted
-
Karadeniz Technical UniversityThe Scientific and Technological Research Council of TurkeyCompletedNutrition | Autism Spectrum Disorder (ASD)Turkey (Türkiye)
-
University of CopenhagenThe Danish Dairy Research Foundation, Denmark; The Ministry of Science, Technology... and other collaboratorsCompletedIncreased Energy Expenditure | Increased SatietyDenmark
-
Massachusetts General HospitalNutricia North AmericaCompletedAutism | Gastrointestinal SymptomsUnited States